标题：SGLT2抑制剂在2型糖尿病患者心血管获益机制

      作者：蒋昭隆 1 综述 刘剑雄 1，2 审校    1.遵义医科大学研究生院，贵州 遵义 563003；2.遵义医科大学附属成都市第二人民医院心内科，四川 成都 610017

      卷次： 2019年30卷19期

      【摘要】 新型降糖药物钠-葡萄糖协同转运蛋白2抑制剂(SGLT2抑制剂)在大型临床试验已证实能为2型糖尿病患者带来心血管获益，包括减少心衰再住院率、心血管死亡率等，但具体机制仍不是很清楚，本文将学习近期相关文献，讨论SGLT2抑制剂在2型糖尿病患者心血管获益机制。
      【关键词】 SGLT2抑制剂；2型糖尿病；大型临床试验；心血管获益；机制
      【中图分类号】 R587.1 【文献标识码】 A 【文章编号】 1003—6350（2019）19—2557—04

Cardiovascular benefit mechanism of SGLT2 inhibitors in patients with type 2 diabetes.
JIANG Zhao-long 1, LIUJian-xiong 1，2. 1. Graduate School, Zunyi Medical University, Zunyi 563003, Guizhou, CHINA; 2. Department of Cardiology,Chengdu Second People's Hospital Affiliated to Zunyi Medical University, Chengdu 610017, Sichuan, CHINA【Abstract】 The new hypoglycemic drug sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor) has beenshown to provide cardiovascular benefits to type 2 diabetic patients in large clinical trials, including reduced heart failurerehospitalization rates, cardiovascular mortality, but the specific mechanism is still not very clear. This article will reviewthe recent literature to discuss the cardiovascular benefit mechanism of SGLT2 inhibitors in patients with type 2 diabetes.
      【Key words】 SGLT2 inhibitor; Type 2 diabetes; Clinical trials; Cardiovascular benefit; Mechanism·综述·doi:10.3969/j.issn.1003-6350.2019.19.032